Sherly Mardiana Selected Research

Therapeutics

11/2020	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.
1/2020	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.
1/2020	CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
1/2020	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
1/2019	Switching on the green light for chimeric antigen receptor T-cell therapy.
1/2019	Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression.
1/2019	Tissue-specific tumor microenvironments influence responses to immunotherapies.
5/2017	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
1/2017	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sherly Mardiana Research Topics

Disease

12	Neoplasms (Cancer) 01/2021 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 11/2020 - 03/2017
2	Leukemia 01/2020 - 05/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Kidney Neoplasms (Kidney Cancer) 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2017

Drug/Important Bio-Agent (IBA)

8	Chimeric Antigen ReceptorsIBA 11/2020 - 01/2017
4	AntigensIBA 01/2020 - 01/2017
3	AutoantigensIBA 05/2017 - 01/2017
2	Adenosine (Adenocard)FDA LinkGeneric 01/2021 - 03/2017
2	EpitopesIBA 01/2020 - 05/2017
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2021
1	Interleukin-15 (Interleukin 15)IBA 11/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	VaccinesIBA 05/2017
1	Interleukin-2 (IL2)IBA 05/2017
1	Chemokine ReceptorsIBA 05/2017

Therapy/Procedure

9	Therapeutics 11/2020 - 01/2017
5	Immunotherapy 01/2020 - 05/2017
1	Hematopoietic Stem Cell Transplantation 01/2020
1	Drug Therapy (Chemotherapy) 01/2020